Venable·IP / PATENT

BMS Files First BPCIA Case for Opdivo Biosimilar Against Amgen

Bristol-Myers Squibb has filed the first BPCIA litigation targeting Amgen's proposed Opdivo (nivolumab) biosimilar ABP 206 in Delaware federal court, asserting seven patents from its $5.9B annual revenue drug.

opdivo-biosimilarbpcia-litigationamgen-bms-patentnivolumab-patentdelaware-patentptab-ipr
Read the original firm alert → Saturday, September 19, 2026

Stay ahead

Join the digest.

One email when the daily AmLaw 100 briefing ships. No noise, no pitch decks — just the grade 4–5 signal.